Skip to main content
Hiroshi Miyamoto, MD, Pathology, Rochester, NY, Strong Memorial Hospital of the University of Rochester

HiroshiMiyamotoMD

Pathology Rochester, NY

Anatomic Pathology

Associate Professor of Pathology, Associate Professor of Urology, Johns Hopkins University School of Medicine

Are you Dr. Miyamoto?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 4 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Hiroshi Miyamoto, MD is a board certified pathologist in Rochester, New York. He is currently licensed to practice medicine in New York and Maryland. He is affiliated with Strong Memorial Hospital of the University of Rochester and F. F. Thompson Hospital.

Education & Training

  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineSelective Pathology, 2008 - 2009
  • Yokohama City University School of Medicine
    Yokohama City University School of MedicineClass of 1988

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2008 - 2026
  • MD State Medical License
    MD State Medical License 2013 - 2017
  • American Board of Pathology Pathology - Anatomic

Publications & Presentations

PubMed

Press Mentions

  • Time-Dependent Efficacy of Combination of Silver-Containing Hydroxyapatite Coating and Vancomycin on Methicillin-Resistant Staphylococcus Aureus Biofilm Formation in Vitro
    Time-Dependent Efficacy of Combination of Silver-Containing Hydroxyapatite Coating and Vancomycin on Methicillin-Resistant Staphylococcus Aureus Biofilm Formation in VitroMarch 2nd, 2021
  • Effects of α1-Adrenergic Receptor Antagonists on the Development and Progression of Urothelial Cancer
    Effects of α1-Adrenergic Receptor Antagonists on the Development and Progression of Urothelial CancerDecember 1st, 2020
  • Enhanced Metastatic Potential in the MB49 Urothelial Carcinoma Model
    Enhanced Metastatic Potential in the MB49 Urothelial Carcinoma ModelMay 15th, 2019

Other Languages

  • Japanese

Hospital Affiliations